Product logins

Find logins to all Clarivate products below.


Renal Cell Carcinoma | Treatment Sequencing | US | 2023

Key benefits and uses

Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.

Identify untapped treatment scenarios and key competitors to aid trial design.

Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.

Discover untapped populations to expand product share and drive strategic decisions.

Questions answered

•Where is my product positioned vs. competitors in the treatment journey?

•What are physicians’ most frequent treatment sequences. Who is benefiting and how can I defend my asset’s share and position?

•What are the market-relevant treatment scenarios according to oncology experts?

•Where are the untapped business opportunities that I can capitalize on?

•How can I optimize trial design and ensure a competitive edge for my pipeline asset?

GEOGRAPHY

United States.

PRIMARY MARKET RESEARCH

Survey of 100 U.S. medical oncologists.

Product description

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.

Related Market Assessment Reports

Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…